Israel's Technion Institute of Technology and Tel Aviv University researchers studied the impact of human stem cells on a rat's spinal cord injuries, Business Insider reports.
The FDA cleared the Omnia Medical VBR.
The global spine biologics market is anticipated to grow through 2023, according to a Transparency Market Research report.
 A new International Journal of Nanomedicine paper compared 3-D-printed PEKK structures with conventional PEEK surfaces for orthopedics.
The FDA cleared SeaSpine's OsteoBallast Demineralized Bone Matrix in Resorbable Mesh.
MD Stem Cells revealed initial results from its study on paraplegia.
The FDA released its regenerative medicine policy guidelines Nov. 16.
While Health Canada's regulatory system has not proven stem cell procedures, patients continue to seek out private clinics to have the experimental treatments performed, according to CDC News.
Here are 65-plus spine surgeons who are participating in clinical trials or have a research focus on biologics and/or stem cells for spine surgery.
National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Numerate a grant.
The global stem cells market is slated to hit $270.5 billion by 2025, according to a Transparency Market Research report.
Global Stem Cells Groups teamed up with Aesthetic Polyclinic.
Golden-based Colorado Pain Care is now providing stem cell therapy to patients.
In August, FDA Commissioner Scott Gottlieb, MD, issued a statement on how the agency will enforce oversight of the stem cell industry moving forward. Dr. Gottlieb noted the FDA is ramping up efforts to prevent dishonest players in the field from selling "dangerously dubious products." Additionally, he wrote the FDA would release a policy on regulations for the new industry this fall.
Amgen is investing in Fortuna Fix, a Canadian stem cell company, according to Endpoints News.
A new study published in Clinical Spine Surgery compares posterior cervical spine complications among patients who receive recombinant human bone morphogenetic protein-2 and those who do not.
The spine biologics global market is anticipated to grow at a 2.07 percent compound annual growth rate through 2020, according to a 360 Market Updates report.
Sarah Heilshorn, PhD, a Stanford (Calif.) University associate professor of materials science and engineering, authored a paper in Nature Materials about growing and preserving neural stem cells, according to Stanford News.
Xtant Medical is in a distribution agreement with curasan, a developer of biomaterials and medical device for bone and tissue regeneration.
SeaSpine commercially launched OsteoStrand Demineralized Bone Fibers, with the first implantations occurring in Connecticut and California.
  • «
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  • »
Page 1 of 50